AMPK/mTOR

Overview

AMP-activated protein kinase (AMPK) and the mechanistic target of rapamycin kinase (mTOR) constitute a functionally opposing signaling axis that sits at the center of cellular energy sensing and metabolic homeostasis. AMPK is a heterotrimeric serine/threonine kinase activated by rising AMP:ATP ratios, oxidative stress, and nutrient deprivation; once active, it phosphorylates downstream substrates to promote catabolic processes including autophagy, fatty acid oxidation, and mitochondrial biogenesis. mTOR, operating primarily within the mTORC1 complex, acts as an anabolic checkpoint that stimulates protein synthesis, lipid biosynthesis, and cell growth while suppressing autophagy. The two kinases are mutually antagonistic: AMPK activation directly phosphorylates and inhibits mTORC1, shifting the cellular program from growth toward energy conservation and quality-control recycling. This reciprocal relationship makes the AMPK/mTOR axis a master regulator of autophagy flux, mitochondrial integrity, inflammatory signaling, and cell survival across virtually every tissue type, and positions it as a high-value pharmacological target in metabolic diseases, neurodegeneration, cancer, and inflammatory conditions.

The biological significance of the AMPK/mTOR axis extends well beyond simple energy bookkeeping. AMPK integrates upstream signals from sirtuin 1 (SIRT1), Forkhead box O3 (FOXO3a), and the SIRT1/FOXO3a/SOD-CAT antioxidant axis to coordinate oxidative stress responses, while mTOR communicates with nutrient-sensing pathways involving AKT and downstream transcription factors such as SREBP-1c that govern lipid metabolism. Dysregulation of either kinase is implicated in a spectrum of pathologies—including type 2 diabetes, Alzheimer's disease, osteoporosis, epilepsy, metabolic dysfunction-associated steatohepatitis (MASH), glycogen storage disorders, and multiple cancers—making the balance between AMPK activity and mTOR suppression a critical determinant of disease progression and therapeutic outcome.

Focus of Latest Publications

Recent publications have continued to position AMPK/mTOR as a central metabolic signaling axis in diverse disease contexts, with most studies examining how its modulation affects stress responses, inflammation, autophagy, and cell fate. In osteoporosis, betulinic acid was reported to protect osteoblasts from hydrogen peroxide-induced inflammatory injury by increasing AMPK phosphorylation, reducing mTOR phosphorylation, and enhancing autophagy, with these effects linked to lower reactive oxygen species production, suppression of NOD-like receptor pyrin domain-containing 3 activation, and improved osteogenic differentiation. In glycogen storage disease type Ib-associated intestinal disease, empagliflozin was shown to restore the colonic mucus barrier through an AMPK-dependent SOX4/MUC2 axis, supporting epithelial repair and goblet cell function. In epilepsy, inhibition of aerobic glycolysis was investigated as a means to suppress ferroptosis via activation of the AMPK-Forkhead box O3a pathway, highlighting AMPK as a mediator of neuroprotective metabolic reprogramming.

Other recent work has focused on AMPK as a pharmacologic target or off-target determinant of drug response. A commentary on prexasertib emphasized that this CHK1 inhibitor also inhibits AMPK, and that this promiscuity may contribute to cancer cell killing. A mechanistic study further reported that prexasertib directly binds AMPK CBS pockets, increases AMPKα Thr172 phosphorylation via CAMKK2 and LKB1, but also acts as an ATP-competitive AMPK inhibitor; together with CHK1 inhibition, this dual targeting was associated with enhanced cytotoxicity and Exo1 hyperactivation. In a related but distinct context, mTOR inhibition was investigated as a strategy to overcome a metabolically hyperactive state and promote all-trans retinoic acid-induced cancer cell differentiation, underscoring the role of mTOR signaling in treatment resistance and differentiation therapy.

AMPK-related signaling has also been linked to neurodegeneration and inflammatory disease. dexmedetomidine was examined in a rat model of Alzheimer's disease with attention to the AMPK/SIRT1 pathway, reflecting interest in energy-sensing mechanisms in metabolically driven neuronal injury. In metabolic dysfunction-associated steatohepatitis, endothelial GSK3β was shown to promote lipotoxic endotheliopathy and liver inflammation, and GSK3 inhibition restored mitochondrial morphology and respiration by regulating AMPK and dynamin-related protein 1, thereby reducing chemokine and adhesion molecule expression. Across these studies, AMPK/mTOR emerges as a recurring node connecting metabolic stress, autophagy, barrier integrity, ferroptosis, and inflammatory signaling, with therapeutic modulation explored through natural compounds, repurposed drugs, kinase inhibitors, and pathway-directed interventions.

Key Publications

NEWJun Mechanotherapeutic biomaterials: Overcoming physical barriers to enhance intratumoral drug delivery in solid tumours. (Biomedical microdevices, 2026, PMID 42334617): "The framework is further extended to incorporate mechanochemical coupling through the representative reactive oxygen species (ROS), AMP-activated protein kinase (AMPK), and sirtuin 1 (SIRT1), linking mechanical stress with redox and metabolic adaptation and informing responsive biomaterial design."
NEWJun Dangerous liaisons: Promiscuous inhibition of CHK1 and AMPK is a lethal affair for cancer cells. (Cell chemical biology, 2026, PMID 42314651): "Guo et al.1 reveal that the Checkpoint kinase 1 (CHK1) inhibitor Prexasertib moonlights as an AMP-activated protein kinase (AMPK) inhibitor that primes cancer cells for destruction."
NEWJun The protective effects of dexmedetomidine via AMPK/SIRT1 pathway activation in a rat model of alzheimer's disease: evidence from preliminary findings. (Molecular biology reports, 2026, PMID 42268445): "The AMP-activated protein kinase (AMPK) / sirtuin-1 (SIRT1) pathway is a key regulator of neuronal energy homeostasis and survival."
May Betulinic acid alleviates the inflammatory injury of osteoblasts in osteoporosis by augmenting autophagy via the AMPK-mTOR signaling pathway. (International journal of molecular medicine, 2026, PMID 42138188): "In addition, BA could enhance the phosphorylation of AMPK in MC3T3-E1 cells treated with H2O2 and reduce the phosphorylation of mTOR, but this effect could be rescued by Compound C (an AMPK blocker)."
Jun Empagliflozin Restores the Colonic Mucous Barrier by an AMPK/SOX4-Dependent Pathway in Glycogen Storage Disease Type Ib. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42133539): "Furthermore, pharmacological inhibition of AMPK suppressed the induction of MUC2, which could be rescued by SOX4 overexpression."
May Inhibition of aerobic glycolysis suppresses ferroptosis via activation of the AMPK-FoxO3a pathway in epileptic rats. (Molecular biology reports, 2026, PMID 42126735): "inhibition of aerobic glycolysis suppresses ferroptosis through activation of the AMP-activated protein kinase (AMPK)-Forkhead box O3a (FoxO3a) signaling pathway"
May mTOR inhibition promotes ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state. (Journal of translational medicine, 2026, PMID 42116148): "mTOR inhibition promotes ATRA-induced cancer cell differentiation by overcoming a metabolic hyperactive state."
May Endothelial Cell Glycogen Synthase Kinase 3β Promotes Lipotoxic Endotheliopathy and Liver Inflammation in MASH. (JCI insight, 2026, PMID 42084928): "Mechanistically, GSK3 inhibition restored lipotoxicity-induced alterations in LSEC mitochondrial morphology and respiration by regulating AMP-activated protein kinase and dynamin-related protein 1."
Jun The cytotoxic effect of prexasertib is a consequence of dual inhibition on both CHK1 and AMPK. (Cell chemical biology, 2026, PMID 42061410): "Prex induced cytotoxicity results from inhibition of CHK1 and AMPK."